Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

WAYPATH PHARMA LLC

UEI: WRM7JGHL7QT3CAGE: 8SSK5

WAYPATH PHARMA LLC is a federal contractor, registered under UEI WRM7JGHL7QT3 and CAGE code 8SSK5. It has been awarded $225,000 in federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

WRM7JGHL7QT3

CAGE Code

8SSK5

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationLimited Liability Company

NAICS Codes

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

WAYPATH PHARMA LLC specializes in scientific and technical consulting services within the pharmaceutical and life sciences sector, leveraging expertise in regulatory science, clinical data analysis, and process optimization for government-funded research initiatives. As a small business operating un...

WAYPATH PHARMA LLC specializes in scientific and technical consulting services within the pharmaceutical and life sciences sector, leveraging expertise in regulatory science, clinical data analysis, and process optimization for government-funded research initiatives. As a small business operating under NAICS 541714, the firm delivers tailored analytical support to complex biopharmaceutical challenges, including protocol design, pharmacovigilance systems, and compliance alignment with FDA and NIH standards. Their technical capabilities center on evidence-based decision frameworks, data integrity management, and lifecycle assessment of therapeutic interventions, with a focus on translating research outcomes into actionable regulatory pathways. The company differentiates itself through methodological rigor in real-world evidence generation and adaptive trial design support, serving as a trusted advisor in navigating evolving federal compliance landscapes. Award history does not provide sufficient detail to identify specific federal agencies or programmatic relationships. Consequently, no definitive patterns of engagement with particular departments or mission areas can be confirmed based on available data. The firm’s primary NAICS classification, 541714, reflects its role as a research and development services provider in the life sciences domain, emphasizing applied research, biostatistical analysis, and regulatory strategy consulting. This positions WAYPATH PHARMA as a niche player in supporting federal initiatives requiring deep scientific acumen, particularly in areas where clinical, analytical, and compliance expertise converge. WAYPATH PHARMA LLC is structured as a small business (2L entity) headquartered in Metairie, Louisiana, with no publicly disclosed government certifications. Its geographic footprint is localized, and its market positioning is defined by specialized technical services rather than broad-scale contract execution. The company operates as a focused provider of high-value scientific consulting, serving clients who require precision-driven, compliant research support in pharmaceutical development.

Key Performance Metrics

Awards Count

1

All time

Active

0

Currently performing

Completed

1

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
- Unknown NAICS$225.0K100%
Awards by Agency Over Time
Awards by Place of Performance

Compete with WAYPATH PHARMA LLC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for WAYPATH PHARMA LLC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in WAYPATH PHARMA LLC's top NAICS codes and agencies

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
The NIH Small Business Technology Transfer (STTR) grant, solicitation PA-27-102, provides early-stage funding for U.S. small business concerns (SBCs) to conduct research and development of commercial products in formal collaboration with non-profit research institutions. The program is designed to enhance health and reduce illness through a phased approach: Phase I focuses on establishing technical merit and feasibility, while Phase II advances the research toward commercialization. Eligible applicants must be for-profit entities located in the U.S., owned more than 50 percent by U.S. citizens or permanent residents, and employ no more than 500 people. The program accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with the latter two being NIH-specific options to accelerate development. Funding limits vary by the awarding NIH Institute or Center, with Phase I budgets typically ranging from 400,000 to 700,000 dollars and Phase II budgets reaching up to 3,000,000 dollars. Applications are evaluated via a peer review system based on an overall impact score, considering commercial potential, technical feasibility, and the quality of the commercialization plan. While clinical trials are generally optional, they require a specific regulatory plan and adherence to strict safety and registration guidelines; notably, several institutes, including NIAID and NIAMS, do not accept clinical trials under this NOFO. Applicants must maintain active registrations in SAM, possess a Unique Entity Identifier, and comply with cybersecurity incident reporting requirements, including notifying HHS within 48 hours of a discovery.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 6 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
The NIH, CDC, and FDA Small Business Innovation Research (SBIR) Grant, solicitation PA-27-100, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products. The program is structured in phases, with Phase I focusing on establishing technical merit and feasibility, and Phase II advancing the project toward commercialization. Eligible applicants include for-profit U.S. businesses with no more than 500 employees. The funding opportunity accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with the latter two being specific to the NIH. Budget limits vary by participating institute, with Phase I awards typically ranging from 400,000 to 700,000 dollars and Phase II awards reaching up to 3,000,000 dollars. Applications are evaluated through a peer review system based on scientific and technical merit, significance, and the suitability of the environment for success. While clinical trials are generally optional, they are prohibited for specific components, including all FDA centers and several NIH institutes such as NIAMS and NIDCR. Recipients must adhere to strict compliance requirements, including maintaining active SAM registration, disclosing foreign relationships, and implementing cybersecurity incident reporting procedures that notify agencies within 48 hours of discovery. All applications must be submitted electronically, with a final expiration date of April 06, 2027.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 6 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The SBIR/STTR Commercialization Readiness Pilot (CRP) Program, solicitation PAR-27-098, is a funding opportunity provided by the National Institutes of Health (NIH) to help U.S.-based small business concerns transition technology from late-stage research and development to full commercialization. This program is specifically available to recipients of prior or active NIH SBIR or STTR Phase II or Phase IIB Strategic Breakthrough awards. The CRP supports activities that bridge the gap to market, including technical assistance for regulatory and intellectual property strategies, manufacturing scale-up, independent replication of key studies, and clinical trials. While significant outsourcing to contract research organizations is permitted, the small business must maintain a substantial role in project oversight and management. Eligible applicants must be for-profit organizations with no more than 500 employees and maintain active registrations in the System for Award Management and the SBA Company Registry. Project periods are limited to a maximum of three years, with budget ceilings varying by participating Institute or Center, ranging from 500,000 dollars to 2 million dollars, or following SBA guidelines for certain institutes. Applications are evaluated via NIH peer review based on scientific and technical merit, commercial potential, and relevance to program priorities. Key submission requirements include a detailed regulatory plan and a CRP progress report, while costs for patent or FDA filing fees and separate Technical and Business Assistance funding are strictly prohibited.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 6 months
View Details